Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Next Previous
Trial Profile

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aducanumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Acronyms EMERGE
  • Sponsors Biogen

Most Recent Events

  • 04 Jan 2024 Results performing genome-wide association studies (GWAS) of ARIA in participants in the ENGAGE and EMERGE trials, published in the Neurology
  • 19 Oct 2023 According to Biogen media release, the company will present pooled ENGAGE/EMERGE integrated placebo-controlled period and long-term extension (LTE) topline results at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.
  • 20 Jul 2023 Results from GRADUATE 1&2 and CLARITY, EMERGE and ENGAGE assessing Re-estimation of drug-specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q-ATN model presented at the Alzheimer's Association International Conference 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top